Literature DB >> 9484382

Controlled trial of ketorolac in tension-type headache.

R N Harden1, D Rogers, K Fink, R H Gracely.   

Abstract

Intramuscular ketorolac 60 mg, meperidine 50 mg plus promethazine 25 mg, and normal saline were compared in acute exacerbations of tension-type headache. Forty-one subjects (30 females and 11 males) were randomized into three groups and evaluated by the McGill Short-Form Pain Questionnaire before treatment, and 0.5, 1, 2, 3, 4, 5, and 6 hours after treatment. All three groups showed a significant treatment effect that persisted for the 6 hours of evaluation. Ketorolac treatment was significantly better than placebo at 0.5 and 1 hour by the Visual Analog Scale (VAS) and Pain Rating Index, and better than meperidine at 2 hours (by the VAS). Meperidine and placebo did not differ at any time point. Ketorolac is effective in short-term treatment of tension-type headache.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484382     DOI: 10.1212/wnl.50.2.507

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Managing the placebo effect: enhancing the signal-to-noise ratio.

Authors:  Kayode A Williams; Norman Harden
Journal:  Curr Pain Headache Rep       Date:  2011-02

Review 2.  Pharmacotherapy of tension-type headaches.

Authors:  Mark J Stillman
Journal:  Curr Pain Headache Rep       Date:  2002-10

3.  Prospective, randomised, double blind, controlled comparison of metoclopramide and pethidine in the emergency treatment of acute primary vascular and tension type headache episodes.

Authors:  M Cicek; O Karcioglu; I Parlak; V Ozturk; O Duman; M Serinken; M Guryay
Journal:  Emerg Med J       Date:  2004-05       Impact factor: 2.740

Review 4.  Current and potential future drug therapies for tension-type headache.

Authors:  Sait Ashina; Messoud Ashina
Journal:  Curr Pain Headache Rep       Date:  2003-12

5.  Tension-type Headache.

Authors:  Rigmor Jensen
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.